Date & Time
October 26, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval
About the Event
MAIA Biotechnology received preliminary data from its Phase 2 Clinical trial for non-small cell lung cancer and the results are very promising. The first 2 patients dosed with THIO continue to be without documented disease progression for 12.2 and 11.5 months, while most patients only live for 3-4 months. In addition, the study shows a preliminary disease control rate (DCR) of 82%, compared to typical DCRs which are in the 25-35% range for chemotherapy.
Join our fireside chat with MAIA CEO, Dr. Vlad Vitoc, to hear more about these results and the company’s other programs which expand the company’s options to treat several cancer indications.